Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Fiche publication
Date publication
mars 2021
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE
Lien Pubmed
Résumé
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize efficacy and safety data of tofacitinib 5 or 10 mg twice daily (BID) in the UC clinical program, stratified by prior tumor necrosis factor inhibitor (TNFi) failure status.
Mots clés
JAK inhibitor, adverse events of special interest, inflammatory bowel disease, tumor necrosis factor antagonist
Référence
Clin Gastroenterol Hepatol. 2021 Mar 5;: